国家药监局修订孟鲁司特制剂说明书，警示语应包含精神副作用

Core Viewpoint - The National Medical Products Administration (NMPA) has announced a unified revision of the instructions for Montelukast formulations, highlighting the potential neuropsychiatric adverse reactions associated with the drug [1] Group 1: Regulatory Changes - The NMPA's announcement includes a warning that neuropsychiatric adverse reactions have been reported in patients of all ages taking Montelukast, including severe reactions such as depression and suicidal tendencies [1] - It is advised that if neuropsychiatric symptoms occur during treatment, the medication should be discontinued and medical attention sought [1] Group 2: Expert Opinions - Ji Lianmei, founder of "Ask the Pharmacist," stated that Montelukast sodium is not the first-choice medication for allergic rhinitis or asthma treatment [1] - The incidence of psychiatric side effects, such as irritability and attention abnormalities, is reportedly higher in children [1] - A thorough assessment of benefits versus risks is recommended before using the medication, and immediate discontinuation and medical consultation are advised if neuropsychiatric symptoms arise during treatment [1]